Actively Recruiting
Finding the Best Dose of N-Acetylcysteine for Adults with Myeloproliferative Neoplasms including Essential Thrombocythemia, Polycythemia Vera, and Myelofibrosis
Led by University of California, Irvine · Updated on 2026-03-10
27
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are studying the best dose of N-acetylcysteine N-AC for patients with myeloproliferative neoplasms MPN, including essential thrombocythemia, polycythemia vera, and myelofibrosis. This phase III open-label trial aims to find the optimal biological dose of N-AC to help manage symptoms related to these blood disorders. Participants will receive oral N-acetylcysteine starting at 600 mg twice daily. If this dose is well tolerated, the dose will increase in steps to 1200 mg and then 1800 mg twice daily. The study monitors safety and symptom improvement at each dose level to determine the best dose. Treatment duration is up to 8 weeks. During the study, participants will undergo blood tests and symptom score assessments to monitor effects and side effects. Researchers will track the optimal biological dose and measure symptom reduction using the MPN-SAF Total Symptom Score over about 9 weeks. The trial includes monitoring for side effects and adherence to treatment and contraception requirements, with participation lasting through treatment and follow-up periods.
CONDITIONS
Brief Title
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
Research Team
A
Angela Fleischman, MD, PhD
U
University of California Irvine Medical Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
